Intelligence Report

Odaia lands $15-million Series C as Publicis Health Media becomes its US agency partner

The University of Toronto spinout, which sells predictive AI tools to pharma and life sciences firms, paired new funding with an exclusive US distribution deal.

INSIGHTEX Editorial Desk

2 min read

Odaia lands $15-million Series C as Publicis Health Media becomes its US agency partnerIntelligence Report

What happened

University of Toronto spinout Odaia, which builds predictive AI software for pharmaceutical and life sciences companies, has closed a Series C round of $15-million USD ($21-million CAD), BetaKit reported. The company announced the financing on Wednesday. Monograph Capital led the round, while Publicis Health Media (PHM) anchored it by combining an investment with a commercial agreement.

Backers from the company's earlier Series A and Series B rounds also took part, among them BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures and Wittington Ventures. Odaia plans to use the capital to develop its AI platform further and expand its share of the market.

Under the commercial deal, PHM will serve as the sole agency partner for Odaia in the US. PHM has also said it intends to integrate the platform for its client companies across health, pharma, biotech and wellness. In a press release, chief executive and co-founder Philip Poulidis said the round will let Odaia deepen its work with current enterprise clients and, through PHM, extend its infrastructure across more of the industry at a quicker pace.

Context

Founded in 2018, Odaia pulls together data from multiple information sources to help pharma sales and marketing teams flag doctors whose patients may need a particular treatment and decide which physicians to prioritize and what messaging to use. While AI has sped up drug development and clinical trials, bringing therapies to market has stayed slow, often depending on lengthy analysis from consulting firms.

SourceBetaKit

The briefing

The week in tech, in one email.

The stories worth your time, every week. Unsubscribe anytime.